BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 16900629)

  • 21. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
    Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
    Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC; Neidhart JA; Triozzi P; Verma S; Nemunaitis J; Quick DP; Mayernik DG; Oette DH; Haynes FA; Holcenberg J
    Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in white blood cells and myeloperoxidase activity in rhG-CSF prophylactic patients receiving cytotoxic chemotherapy.
    Charuruks N; Krailadsiri P; Voravud N; Nitipaijit N; Srisink N; Settapiboon R
    J Med Assoc Thai; 1994 Aug; 77(8):426-33. PubMed ID: 7533203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
    Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
    Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [High-dose chemotherapy supported by peripheral blood stem cells to treat intermediate--and high-grade non-Hodgkin's lymphomas].
    Ji Y; Ji S; Ju X
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):471-5. PubMed ID: 9387307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Protecting infection by using rhG-CSF in patients with lung cancer during chemotherapeutic courses].
    Zhang S; Liu X; Fang J
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jun; 21(6):355-7. PubMed ID: 11326893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mobilization of autologous peripheral blood stem cells with etoposide and recombinant human granulocyte colony stimulating factor in malignant tumor patients].
    Shi YK; He XH; Han XH; Yang JL; Liu P; Zhang CG; Ai B
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):360-3. PubMed ID: 15312348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Randomized controlled study of leucomax (recombinant human granulocyte-macrophage colony stimulating factor, rhGM-CSF) in the treatment of cancer chemotherapy-induced leucopenia].
    Feng F; Zhou L
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):451-3. PubMed ID: 10920943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    Jiang Y; Zhang J; Zhong J; Liao H; Zhang J; Liu Y; Liang Y; Li H
    BMC Cancer; 2023 Jul; 23(1):702. PubMed ID: 37495949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer.
    Soda H; Oka M; Fukuda M; Kinoshita A; Sakamoto A; Araki J; Fujino S; Itoh N; Watanabe K; Kanda T; Nakano M; Hara K
    Cancer Chemother Pharmacol; 1996; 38(1):9-12. PubMed ID: 8603458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
    Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
    Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
    Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
    Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
    Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.